- Home
- CPRX
as 03-25-2025 10:33am EST
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | CORAL GABLES |
| Market Cap: | 2.6B | IPO Year: | 2006 |
| Target Price: | $32.50 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.31 | EPS Growth: | 107.94 |
| 52 Week Low/High: | $14.47 - $26.16 | Next Earning Date: | 05-07-2025 |
| Revenue: | $491,734,000 | Revenue Growth: | 23.49% |
| Revenue Growth (this year): | 15.17% | Revenue Growth (next year): | 8.28% |
Stock Insider Trading Activity of Catalyst Pharmaceuticals Inc. (CPRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| INGENITO GARY | CPRX | Chief Med. & Reg. Officer | Mar 5 '25 | Sell | $21.88 | 225,000 | $4,894,609.68 | 68,873 | |
| Del Carmen Jeffrey | CPRX | Chief Commercial Officer | Mar 3 '25 | Sell | $22.89 | 30,423 | $696,382.47 | 0 | |
| Elsbernd Brian | CPRX | Chief Compliance/Legal Officer | Mar 3 '25 | Sell | $23.08 | 62,975 | $1,446,932.75 | 188,564 |
Latest Catalyst Pharmaceuticals Inc. News
CPRX Breaking Stock News: Dive into CPRX Ticker-Specific Updates for Smart Investing
Zacks
9 days ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Insider Monkey
12 days ago
Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment?
Simply Wall St.
21 days ago
We Think Catalyst Pharmaceuticals' (NASDAQ:CPRX) Robust Earnings Are Conservative
Argus Research
21 days ago
CPRX: Raising target price to $24.00
GlobeNewswire
22 days ago
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
Simply Wall St.
a month ago
Catalyst Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
GuruFocus.com
a month ago
Catalyst Pharmaceuticals Inc (CPRX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...
Motley Fool
a month ago
Here's What's Driving Catalyst Pharmaceuticals Stock 8% Higher Today
Compare CPRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CPRX Catalyst Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.